Georgalas Ilias, Petrou Petros, Papakonstantinou Dimitrios, Droumouchtsis Vagelis, Tservakis Ioannis
Department of Ophthalmology, University of Athens , Athens , Greece and.
Cutan Ocul Toxicol. 2015;34(3):257-9. doi: 10.3109/15569527.2014.951450. Epub 2014 Sep 8.
The use of a slow-release dexamethasone implant (Ozurdex) for the treatment of post-operative macular edema (ME) in a vitrectomized eye has never been used before. We herein report a case of a 70-year-old woman with post-vitrectomy ME refractory to topical, sub-tenon's and intravitreal steroid administration that responded well to the implantation of a slow-release dexamethasone implant (Ozurdex) in a previously vitrectomized eye.
Interventional case presentation.
One week post-implantation, the central retinal thickness was reduced to 383 μm from 640 μm and the best corrected visual acuity (BCVA) improved to 6/36 from counting fingers (CF). At six months' follow-up visit, the improvement of the ME was sustained as indicated by the optical coherence tomography (OCT) measurements and the BCVA remained stable. No serious topical or systemic adverse events were observed from the implantation of Ozurdex in the vitrectomized eye.
The use of Ozurdex in our case resulted in rapid improvement of the post-operative resistant ME. To the best of our knowledge, this is the first report in the literature demonstrating the use of the slow-release dexamethasone implant (Ozurdex) to treat post-operative ME in a vitrectomized eye.
缓释地塞米松植入物（Ozurdex）用于治疗玻璃体切除术后眼的黄斑水肿（ME）此前从未有过报道。我们在此报告一例70岁女性患者，其玻璃体切除术后黄斑水肿对局部、球周及玻璃体内注射类固醇治疗均无效，但在先前已行玻璃体切除术的眼中植入缓释地塞米松植入物（Ozurdex）后反应良好。
介入性病例报告。
植入后一周，视网膜中央厚度从640μm降至383μm，最佳矫正视力（BCVA）从指数（CF）提高到6/36。在六个月的随访中，光学相干断层扫描（OCT）测量显示黄斑水肿持续改善，最佳矫正视力保持稳定。在玻璃体切除眼中植入Ozurdex未观察到严重的局部或全身不良事件。
在我们的病例中使用Ozurdex使术后难治性黄斑水肿迅速改善。据我们所知，这是文献中首次报道使用缓释地塞米松植入物（Ozurdex）治疗玻璃体切除术后的黄斑水肿。
